News Related to Celea Therapeutics

Related coverage linked through entity extraction aliases.

Deupirfenidone Receives Orphan Drug Designation from FDA and European Commission for IPF

Feb 20, 2026

PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.

PureTech's Deupirfenidone Receives FDA and EU Orphan Drug Designation for IPF

Feb 20, 2026

PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.